Belite Bio, Inc
147.33USD
-2.9400 (-1.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BLTE.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.77▲ | -$0.82 | 4 | 1 |
| Next quarter | -$0.9▲ | -$0.95 | 3 | 2 |
| Current year | -$2.94▲ | -$3.3 | 3 | 1 |
| Next year | $2.26▲ | $0.95 | 5 | 2 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.78 | -$0.7 | +0.08 (+9.9%) |
| 2026-03-31 | -$0.64 | -$0.68 | -0.04 (-5.8%) |
| 2025-12-31 | -$0.54 | -$0.7 | -0.16 (-30.3%) |
| 2025-09-30 | -$0.49 | -$0.65 | -0.16 (-32.7%) |
60 ratings from 9 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | $245 | Oct 15, 2026 |
| Mizuho | Maintained | Outperform | $220 $234 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $214 $245 | Sep 8, 2026 |
| Canaccord Genuity | Initiated | Buy | $303 | Sep 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $201 $206 | Aug 14, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $266 $270 | Aug 14, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $200 $214 | Aug 12, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Jun 15, 2026 |
| Mizuho | Maintained | Outperform | $223 $215 | May 26, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | May 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Apr 22, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $200 | Apr 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $185 $200 | Mar 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $191 $201 | Mar 3, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $200 $266 | Mar 3, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $185 | Jan 28, 2026 |
| B of A Securities | Initiated | Buy | $195 | Jan 26, 2026 |
| Morgan Stanley | Initiated | Overweight | $191 | Jan 6, 2026 |
| Mizuho | Upgraded from Neutral | Outperform | $105 $194 | Dec 2, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $98 $185 | Dec 1, 2025 |
| Mizuho | Initiated | Neutral | $105 | Nov 20, 2025 |
| Benchmark | Maintained | Buy | $80 $132 | Oct 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $100 $98 | Sep 15, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Jul 3, 2025 |
| Cantor Fitzgerald | Reiterated | Overweight | — | May 15, 2025 |
70 filings from 8 insiders · 0 buy / 0 sell over 6m
Officers and directors of BLTE, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 200 | $163.63 | $33k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 24 | $164.64 | $4k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 120 | $165.49 | $20k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 50 | $166.44 | $8k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 78 | $167.59 | $13k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 12 | $168.21 | $2k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 14 | $169.36 | $2k | Oct 1, 2026 |
| Scholl Hendrik PeterOfficer, Chief Medical Officer | Sellindirect | 2 | $170.02 | $340 | Oct 1, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 2.2k | $194.28 | $427k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.1k | $195.60 | $806k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.5k | $196.47 | $879k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 4.6k | $197.23 | $908k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 2.6k | $198.05 | $507k | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 2.4k | $194.33 | $466k | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.1k | $195.62 | $1.19M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 6.1k | $196.54 | $1.19M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 8.8k | $197.36 | $1.73M | Sep 8, 2026 |
| Lin Yu-HsinDirector; Officer, Chief Executive Officer | Sell | 2.7k | $198.09 | $535k | Sep 8, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 1.6k | $180.16 | $294k | Sep 4, 2026 |
| Chuang Hao-YuanDirector; Officer, Chief Financial Officer | Sell | 2.0k | $181.05 | $362k | Sep 4, 2026 |
No analyst notes on BLTE yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 7 | 0 | 0 | 0 | Buy1.78 |
| 1 mo ago | 2 | 7 | 0 | 0 | 0 | Buy1.78 |
| 2 mo ago | 2 | 6 | 0 | 0 | 0 | Buy1.75 |
| 3 mo ago | 2 | 6 | 0 | 0 | 0 | Buy1.75 |
Members whose judged calls on BLTE have played out most reliably.
No settled calls on BLTE yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice